Invesco Ltd. Contrafect Corp Transaction History

Invesco Ltd.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 17, 2021	SELL	$3.58 - $4.9 $47,102 - $64,469	-13,157 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$4.46 - $6.68 $2,992 - $4,482	671 Added 5.37%	13,157 $63,000
Q4 2020 Feb 16, 2021	SELL	$5.05 - $6.4 $13,231 - $16,768	-2,620 Reduced 17.34%	12,486 $63,000
Q3 2020 Nov 16, 2020	BUY	$5.05 - $6.99 $191 - $265	38 Added 0.25%	15,106 $80,000
Q2 2020 Aug 14, 2020	BUY	$4.69 - $7.81 $70,668 - $117,681	15,068 New	15,068 $96,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

Stay updated on Invesco Ltd. with notifications on news.